Financial Performance Highlights
Revenue:
- Q1 FY27 operating revenue: ₹840.8 crores, up 35.6% YoY from ₹620 crores in Q1 FY26
Regional Revenue Breakdown:
- North America: ₹377 crores (45% of total), up 15.1% YoY
- UK and Europe: ₹356 crores (42% of total), up 74.7% YoY (highest ever quarterly revenue for region)
- Australia and New Zealand: ₹88 crores, up 53.7% YoY
- Rest of World: ₹20 crores
Profitability Metrics:
- Gross profit: ₹497.3 crores, up 38.9% YoY from ₹358.2 crores
- Gross margin: 59.1% (expanded 138 bps YoY, 478 bps QoQ)
- EBITDA: ₹213 crores, up 112.8% YoY from ₹100.1 crores
- EBITDA margin: 25.3% (expanded 919 bps YoY, 251 bps QoQ)
- PAT: ₹159.4 crores, up 173.9% YoY from ₹58.2 crores
- PAT margin: 18.4% (improved from 9.3% YoY and 16.7% QoQ)
Cash Flow and Balance Sheet:
- Cash from operations: ₹185 crores
- Net capex: ₹33 crores
- Free cash flow: ₹152 crores
- Working capital cycle: 132 days (improved from 159 days in Q1 FY26 and 138 days in FY26)
- R&D spend: ₹23.2 crores (2.8% of revenue) vs ₹12.1 crores (2.0%) in Q1 FY26
- Cash balance: ₹1,058 crores (vs ₹711 crores in Q1 FY26)
- Net cash: ₹1,031 crores
Strategic Developments and Acquisitions
European Expansion:
- Completed acquisition of QliniQ B.V in Netherlands (effective date April 1, 2026)
- QliniQ contributed approximately ₹44 crores revenue in Q1 FY27
- Completed acquisition of ABCnow GmbH, Germany (consolidation commencing from Q2 FY27)
- Established Marksans Pharma Europe in Ireland and Marksans Pharma GmbH in Germany
- Expected QliniQ revenue for full year: ₹150-175 crores
- Target for Europe business: ~₹180 crores for FY27
- Long-term target: Europe geography to reach ~₹1,000 crores in 3-5 years
Manufacturing Update:
- Goa Unit 2 (Teva facility) currently generating ~₹50+ crores revenue (60-65% of projected ₹80 crores capacity)
- 65-70% of sales manufactured in India
- Exploring additional manufacturing capacity requirements for next 1-2 years
Management Guidance and Outlook
FY27 Guidance:
- Revenue growth: 15-20%
- EBITDA margin: 21-22%
- All geographies expected to contribute to growth
Long-term Targets:
- Double revenue within next five years
- Become top global consumer healthcare company by 2030
- US market target: $300 million near-term, $400 million in 5 years
Regional Expectations:
- Europe: Strong growth continuation with new acquisitions
- US: Momentum expected to strengthen in coming quarters, price erosion in single digits
- Australia/New Zealand: Underlying business remains healthy, momentum to build through year
- Canada: Product filings underway
Capital Allocation Strategy
- Cash balance of ₹1,058 crores to fuel inorganic growth strategies
- Focused on European expansion through acquisitions
- Disciplined approach to M&A with focus on return on investment
- Conservative cash management approach (FDs and current accounts)
- No plans for index investing or higher-risk yield products
Product and Market Strategy
- Working to double product portfolio in every country within 2-3 years
- R&D focus on differentiated product dosage forms
- Market mix:
- UK: 55% Rx, 45% OTC
- Europe: Expected 80-85% Rx, 15-20% OTC
- US: Primarily OTC-driven (historically 95% OTC, potentially shifting to 85% OTC)
- No active pursuit of backward integration, but developing DMF IPs and exploring CRAMS business
Regulatory Environment
- Three USFDA-approved plants globally
- No definite timeline for next USFDA inspection (one plant audited less than 12 months ago)
- Monitoring potential US trade policy changes (200% duty mention), but considering it premature to react
Q&A Highlights
- Gross margin sustainability: Expected around 55-56% range due to geopolitical factors (war, crude prices, transportation costs)
- Working capital improvement driven by inventory unwinding
- Order book remains strong across geographies
- Germany entity expected to generate revenue in early Q3 FY27
- Ireland entity revenue expected in next financial year (FY28)
- Rest of World markets facing challenges due to geopolitical issues and transportation hurdles